Posted on 6/13/2019
Senseonics, a company out of Germantown, Maryland, won FDA approval for its Eversense continuous glucose monitoring system. The system is intended to be used instead of traditional finger prick tests to make diabetes-related decisions. This is a giant step for the company, which has developed a technology that combines a tiny implant with a wearable transmitter to continuously measure glucose for 90 days at a time.
The Eversense implant is only 3.5 mm x 18 mm in size, and it is injected under the skin of the upper arm. The transmitter reads what the implant sensor is measuring, and sends regular updates to the patient’s paired smartphone, which keeps track of historical numbers. It can be removed at any time to recharge it or for the patient to take a shower, for example.
This t...